Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Ulcerative Colitis
Last updated July 24, 2020
Status:
Concluded with an LOI
Manufacturer:
Kaleo Inc
Indication:
For the emergency treatment of severe acute allergic reactions (anaphylaxis).
Last updated July 22, 2020
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Febrile neutropenia in non-myeloid malignancies
Last updated July 22, 2020
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Advanced or Metastatic Breast Cancer
Last updated July 14, 2020
Kisqali (with fulvestrant) (ribociclib with fulvestrant)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Advanced or Metastatic Breast Cancer
Last updated July 14, 2020
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma
Last updated June 19, 2020
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Neutropenia in various indications (Prevention or treatment)
Last updated June 17, 2020
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Last updated June 12, 2020
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Multiple Myeloma
Last updated June 10, 2020
Status:
Negotiations were not pursued
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Systemic Mastocytosis
Last updated May 25, 2020